Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KNTE

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

Kinnate Biopharma logo

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$2.64
$2.68
50-Day Range
$2.45
$2.66
52-Week Range
$1.04
$7.18
Volume
2.81 million shs
Average Volume
418,678 shs
Market Capitalization
$125.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Remove Ads
Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

KNTE Stock News Headlines

Kinetic Engineering Ltd (KNTE)
KNTE Kinnate Biopharma Inc.
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More Headlines

KNTE Stock Analysis - Frequently Asked Questions

Kinnate Biopharma Inc. (NASDAQ:KNTE) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.73).

Kinnate Biopharma (KNTE) raised $170 million in an initial public offering (IPO) on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kinnate Biopharma investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Canopy Growth (CGC) and DraftKings (DKNG).

Company Calendar

Last Earnings
5/11/2023
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-116,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.06 per share
Price / Book
0.52

Miscellaneous

Free Float
27,532,000
Market Cap
$125.13 million
Optionable
Optionable
Beta
1.38
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:KNTE) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners